{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-014016","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.221044+00:00","generated_at":"2026-05-30T02:52:32.840418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%","bullets":["Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.","Diagnostics segment revenue $0.5M (+38% YoY); Therapeutic Device $6.5M (+9%).","Net loss $6.7M vs $0.5M loss a year ago (prior year included $2.2M acquisition gain).","Adjusted non-GAAP EBITDA loss $4.3M; operating cash burn ~$5.2M, adjusted $4.0M.","Cash & securities $77.8M at Sept 30, down from $83.0M at June 30; no guidance change."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-014016","json":"https://secwatch.observer/filing/0001654954-24-014016.json","markdown":"https://secwatch.observer/filing/0001654954-24-014016.md","text":"https://secwatch.observer/filing/0001654954-24-014016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424014016/0001654954-24-014016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424014016/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:52:32.840418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}